相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review
S-M Huang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Transporter-Mediated Drug-Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies
K. Yoshida et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses
J. Honkalammi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Long-lasting Inhibitory Effects of Cyclosporin A, but Not Tacrolimus, on OATP1B1-and OATP1B3-mediated Uptake
Yoshihisa Shitara et al.
DRUG METABOLISM AND PHARMACOKINETICS (2012)
Repaglinide A Review of Its Use in Type 2 Diabetes Mellitus
Lesley J. Scott
DRUGS (2012)
Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation
Ping Zhao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Characterization of Organic Anion Transporting Polypeptide (OATP) Expression and Its Functional Contribution to the Uptake of Substrates in Human Hepatocytes
Emi Kimoto et al.
MOLECULAR PHARMACEUTICS (2012)
Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions
Manthena V. S. Varma et al.
PHARMACEUTICAL RESEARCH (2012)
Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications
Aleksi Tornio et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
A Comprehensive Assessment of Repaglinide Metabolic Pathways: Impact of Choice of In Vitro System and Relative Enzyme Contribution to In Vitro Clearance
Carolina Saell et al.
DRUG METABOLISM AND DISPOSITION (2012)
Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data
Hannah M. Jones et al.
DRUG METABOLISM AND DISPOSITION (2012)
Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models
Eleanor J. Guest et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans
J. Honkalammi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Evaluation of CYP2C8 Inhibition In Vitro: Utility of Montelukast as a Selective CYP2C8 Probe Substrate
Brooke M. VandenBrink et al.
DRUG METABOLISM AND DISPOSITION (2011)
Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses
Johanna Honkalammi et al.
DRUG METABOLISM AND DISPOSITION (2011)
pH-Sensitive Interaction of HMG-CoA Reductase Inhibitors (Statins) with Organic Anion Transporting Polypeptide 2B1
Manthena V. Varma et al.
MOLECULAR PHARMACEUTICS (2011)
Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins
Michael J. Knauer et al.
CIRCULATION RESEARCH (2010)
Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin
Rune Amundsen et al.
DRUG METABOLISM AND DISPOSITION (2010)
Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data
Michael Gertz et al.
DRUG METABOLISM AND DISPOSITION (2010)
Investigation of the Pharmacokinetic Interactions of Deferasirox, a Once-Daily Oral Iron Chelator, With Midazolam, Rifampin, and Repaglinide in Healthy Volunteers
Andrej Skerjanec et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-Pass Elimination
Manthena V. S. Varma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Membrane transporters in drug development
Kathleen M. Giacomini et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes
Peter J. Kilford et al.
DRUG METABOLISM AND DISPOSITION (2009)
Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans
Takao Watanabe et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: Evidence for mechanism-based inhibition of CYP2C8 in vivo
A. Tornio et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro
Odette A. Fahmi et al.
DRUG METABOLISM AND DISPOSITION (2008)
Multiple inhibition mechanisms and prediction of drug-drug interactions: Status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions
Laura K. Hinton et al.
PHARMACEUTICAL RESEARCH (2008)
Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1
R. Nakagomi-Hagihara et al.
XENOBIOTICA (2007)
Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions
Trudy Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Transporters as a determinant of drug clearance and tissue distribution
Y Shitara et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate
TM Polasek et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport
Yi-an Bi et al.
DRUG METABOLISM AND DISPOSITION (2006)
The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions
RS Obach et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions
BW Ogilvie et al.
DRUG METABOLISM AND DISPOSITION (2006)
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro:: Effect of fibrates and rifampicin
LI Kajosaari et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2005)
Cyclosporine markedly raises the plasma concentrations of repaglinide
LI Kajosaari et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases
T Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin:: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil
Y Shitara et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Polymorphism in CΥP2C8 is associated with reduced plasma concentrations of repaglinide
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone
M Niemi et al.
DIABETOLOGIA (2003)
CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide
TB Bidstrup et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide
V Hatorp et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Gemfibrozil greatly increases plasma concentrations of cerivastatin
JT Backman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Rifampin decreases the plasma concentrations and effects of repaglinide
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Pharmacokinetics of repaglinide in subjects with renal impairment
TC Marbury et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
分享论文
